Antituberculosis Therapy and Imatinib for Chronic Myeloid Leukemia
نویسندگان
چکیده
منابع مشابه
Evaluation of Thyroid Dysfunction during Imatinib Therapy in Chronic Myeloid Leukemia
Background: Imatinib mesylate is the first generation of Tyrosine kinase inhibitors (TKI) and highly effective in the treatment of chronic myeloid leukemia (CML). We aimed to evaluate thyroid function at baseline and at 1, 3, 6 and 12 months after initiation of Imatinib mesylate therapy in 20 newly diagnosed BCR-ABL positive CML patients. Methods: This study was done during 2013-2014, 20 new c...
متن کاملTherapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
Chronic myeloid leukemia (CML) results from the clonal expansion of pluripotent hematopoietic stem cells containing the active BCR/ABL fusion gene produced by a reciprocal translocation of the ABL1 gene to the BCR gene. The BCR/ABL protein displays a constitutive tyrosine kinase activity and confers on leukemic cells growth and proliferation advantage and resistance to apoptosis. Introduction o...
متن کاملMyelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.
During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Philadelphia chromosome (Ph)-negative cells. These abnormalities are frequently transient and their clinical consequence is unclear. Although some reports have suggested that the abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has no...
متن کاملImatinib in chronic myeloid leukemia elderly patients
Leukemia (CML) reported in clinical trials is generally of 50-55 years; it is higher (more than 60 years) in epidemiologic registries and in observational studies [1]. Therefore, a significant proportion of CML patients are " elderly " , according to the most widely accepted definition of " old person " (age > 65 years). Prior to imatinib (IM) introduction, an orally taken tyrosine kinase inhib...
متن کاملImatinib: can one outwit chronic myeloid leukemia?
were most notable in large-sized platelet subpopulations. The implication is that the bleeding tendency in these disorders is secondary to abnormal in vivo platelet-vessel wall and platelet-platelet interactions caused by decreased levels of GPIb-VIX. An interesting finding given the necessary interconnection between cytoskeletal components and membrane proteins. This suggested mechanism deserv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Infectious Diseases
سال: 2006
ISSN: 1058-4838,1537-6591
DOI: 10.1086/507904